Principia Biopharma is a clinical-stage biopharmaceutical company focused on bringing transformative therapies to patients with serious immune-mediated diseases by changing the way small molecules are developed. Our mission is to make best-in-class medicines to address unmet medical needs by changing the way small molecule drugs are designed. We are a late-stage biopharmaceutical company developing next-generation therapies — immuno-modulators — that have the potential to transform the treatment of underserved patients who have immune-mediated diseases. We design novel therapies using our proprietary and unique Tailored Covalency® platform. We have developed both reversible covalent and irreversible covalent small molecule drugs that bind very specifically to targets in the body that are central to immune disorders.